Clinical characteristics of the patients in the validation set*
Characteristic . | Value . |
|---|---|
| Mean age, y (range) | 38.7 (10-86) |
| Sex, no. (%) | |
| Male | 117 (49.8) |
| Female | 118 (50.2) |
| Diagnosis, no. (%) | |
| Nodular sclerosis HL | 138 (58.7) |
| Mixed cellularity HL | 79 (33.6) |
| Lymphocyte-rich classic HL | 12 (5.1) |
| Lymphocyte-depleted HL | 6 (2.5) |
| Stage, no. (%) | |
| I | 31 (13.2) |
| II | 115 (48.9) |
| III | 55 (23.4) |
| IV | 34 (14.5) |
| IPS, no. (%) | |
| 0-2 | 172 (74.5) |
| 3 or more | 59 (25.5) |
| Outcome, no. (%) | |
| FR | 197 (86) |
| UR | 32 (14) |
| Follow-up, no. (%) | |
| ACR | 185 (78.4) |
| AWD | 17 (7.2) |
| DOD | 31 (14.0) |
Characteristic . | Value . |
|---|---|
| Mean age, y (range) | 38.7 (10-86) |
| Sex, no. (%) | |
| Male | 117 (49.8) |
| Female | 118 (50.2) |
| Diagnosis, no. (%) | |
| Nodular sclerosis HL | 138 (58.7) |
| Mixed cellularity HL | 79 (33.6) |
| Lymphocyte-rich classic HL | 12 (5.1) |
| Lymphocyte-depleted HL | 6 (2.5) |
| Stage, no. (%) | |
| I | 31 (13.2) |
| II | 115 (48.9) |
| III | 55 (23.4) |
| IV | 34 (14.5) |
| IPS, no. (%) | |
| 0-2 | 172 (74.5) |
| 3 or more | 59 (25.5) |
| Outcome, no. (%) | |
| FR | 197 (86) |
| UR | 32 (14) |
| Follow-up, no. (%) | |
| ACR | 185 (78.4) |
| AWD | 17 (7.2) |
| DOD | 31 (14.0) |
IPS indicates International Prognostic Score; FR, favorable treatment response; UR, unfavorable treatment response (see “Patient samples”); ACR, alive in complete remission; AWD, alive with disease; DOD, dead of disease.
The validation set of patients was selected from a previous series28 on the basis of the availability of tumor biopsy specimens. All patients were HIV negative.